Weight loss implants to increase compliance and cut admin burden for patients
Obesity is a chronic metabolic disease characterised by excess body weight and comorbidities that can become life-threatening. The obesity treatment landscape has immensely improved in the past few years, but compliance remains a problem for patients. According to GlobalData, the next generation of obesity therapies will see candidates improving patients' experience, from higher tolerability profiles to lower dosage frequency and better routes of administration.
Vivani Medical, an emerging biopharmaceutical company in the metabolic diseases space, is developing subdermal implants that are changed once or twice per year, delivering GLP-1R agonist with no need for a weekly injection.
Thanks to their NanoPortal implant technology, NPM-115 and NPM-139 will soon be able to deliver exenatide and semaglutide respectively in patients with obesity. The company has recently completed enrolment for its first-in-human trial, LIBERATE-1, investigating NPM-115. A trial of NPM-139 is expected to follow in due course.
In late March 2025, results from NPM-139's preclinical study were announced. It confirmed that the treatment resulted in close-to-20% placebo-adjusted weight loss from a single administration and that this semaglutide implant could be eligible for once-yearly administration.
Key opinion leaders (KOLs) interviewed by GlobalData have stated that a twice-yearly or once-yearly therapy administration would be a great improvement from the current once-weekly administration. While a once-monthly injection is not seen as a major difference, experts seem enthusiastic about longer interval options. The self-administering nature of injection pens is not ideal, according to KOLs, as dosing errors can occur and patients can forget about them. Instead, a once or twice-yearly injection could be performed by a doctor or in a hospital setting, reducing patient responsibility and risk of error.
The application of the implant will likely be different to a small subcutaneous injection, so patients' perspectives on the implant administration experience will be crucial for treatment uptake and the perception of these candidates. Reduced frequency of administration is very encouraging for patient compliance, and if the implant delivery is smooth and safe, it could secure a large number of patients who are adverse to weekly injections and self-administration. This is especially beneficial as they are likely to need lifelong treatment.
"Weight loss implants to increase compliance and cut admin burden for patients" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Study: Real-world results of GLP-1 drugs don't match trials
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says. People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported Tuesday in the journal Obesity. That's far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss, researchers said. "Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial," lead investigator Hamlet Gasoyan said in a news release. He is a researcher at the Cleveland Clinic Center for Value-Based Care Research. People taking the drugs in real-world settings appear to be more likely to quit taking the meds, researchers said. They also might be prescribed lower dosages in clinical practice than were used in the drug trials. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. For this study, researchers tracked nearly 7,900 patients being treated by the Cleveland Clinic for severe obesity, of whom about 6,100 were prescribed semaglutide and the rest tirzepatide. Average body weight loss after a year was nearly 9% for the whole group, results show. But weight loss varied based on when a person stopped taking the drugs, researchers found. Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says. Those who stayed on their medications lost an average 12% body weight. Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well. People who stayed on their meds and received high doses lost nearly 14% of their body weight with semaglutide and 18% with tirzepatide. "Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of health care providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions," Gasoyan said. Overall, patients had higher odds of losing 10% or more of their body weight after a year if they remained on their meds, were prescribed a high dosage, were taking tirzepatide rather than semaglutide, and were female, results show. The cost of the drugs and problems were insurance were a common reason for patients stopping GLP-1 treatment, along with side effects and medication shortages, researchers said. Staying on the GLP-1 meds particularly helped the nearly 17% of patients who had prediabetes, a condition in which elevated blood sugar levels increase a person's risk of developing Type 2 diabetes. About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier. "Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important," Gasoyan said. "This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes." A follow-up study is in the works to better track why patients stop taking their GLP-1 drugs, researchers said. More information Harvard Medical School has more on GLP-1 drugs. Copyright © 2025 HealthDay. All rights reserved.


The Hill
an hour ago
- The Hill
Lawmakers urge Trump administration to clamp down on illicit GLP-1 sales
A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing these drugs without knowing the product could be fraudulent. North Carolina Reps. Brad Knott (R) and Deborah Ross (D) wrote to Food and Drug Administration (FDA) Commissioner Marty Makary, Homeland Security Secretary Kristi Noem and U.S. Attorney General Pam Bondi, imploring them to end the sale of 'counterfeit, research-grade and illegal copycats' of popular GLP-1 medications. When the commercial, branded versions of tirzepatide and semaglutide were declared to no longer be in shortage, compounding pharmacies were disallowed from continuing to sell compounded versions of those drugs. While telehealth companies have transitioned away from compounded versions, state officials have warned that 'copycat' drugs have proliferated in the months since the shortages ended. Earlier this year, the National Association of Attorneys General sent a letter to the FDA to warn that 'counterfeit GLP-1 drugs have infiltrated the U.S. supply chain from China, Turkey, India, and other foreign sources.' According to the attorneys general, online retailers sell the active ingredient for the GLP-1s under the claim that they're 'for research purposes only' or 'not for human consumption' while still marketing them to consumers on social media. The FDA issued a warning in April, telling consumers to not take counterfeit Ozempic. The drug's manufacturer, Novo Nordisk, had alerted the agency that several hundred units of counterfeit product had entered the U.S. supply chain. At the time, the FDA said it was aware of six adverse events associated with the counterfeit products. Though the FBI issued a public service warning soon after the letter from the attorneys general was sent, Knott and Ross said raising public awareness wasn't enough. 'FDA has received hundreds of reports of adverse events, even some resulting in the hospitalization and death of patients who used illicit GLP-1s,' they wrote. 'This is likely a significant underreporting of adverse events experienced by patients because federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA.' The lawmakers asked that the Trump Cabinet members fully use 'the legal tools at your discretion' to further detect illicit and enforce U.S. drug standards. Sen. Thom Tillis (R-N.C.) sent his own letter to Cabinet members, calling for enhanced collaboration among agencies like FDA, U.S. Customs and Border Protection and the Justice Department in order to stop the counterfeit products from reaching the supply chain in the first place. The Hill has reached out to the agencies named in the letter for comment.
Yahoo
3 hours ago
- Yahoo
Study: Real-world results of GLP-1 drugs don't match trials
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says. People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported Tuesday in the journal Obesity. That's far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss, researchers said. "Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial," lead investigator Hamlet Gasoyan said in a news release. He is a researcher at the Cleveland Clinic Center for Value-Based Care Research. People taking the drugs in real-world settings appear to be more likely to quit taking the meds, researchers said. They also might be prescribed lower dosages in clinical practice than were used in the drug trials. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. For this study, researchers tracked nearly 7,900 patients being treated by the Cleveland Clinic for severe obesity, of whom about 6,100 were prescribed semaglutide and the rest tirzepatide. Average body weight loss after a year was nearly 9% for the whole group, results show. But weight loss varied based on when a person stopped taking the drugs, researchers found. Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says. Those who stayed on their medications lost an average 12% body weight. Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well. People who stayed on their meds and received high doses lost nearly 14% of their body weight with semaglutide and 18% with tirzepatide. "Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of health care providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions," Gasoyan said. Overall, patients had higher odds of losing 10% or more of their body weight after a year if they remained on their meds, were prescribed a high dosage, were taking tirzepatide rather than semaglutide, and were female, results show. The cost of the drugs and problems were insurance were a common reason for patients stopping GLP-1 treatment, along with side effects and medication shortages, researchers said. Staying on the GLP-1 meds particularly helped the nearly 17% of patients who had prediabetes, a condition in which elevated blood sugar levels increase a person's risk of developing Type 2 diabetes. About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier. "Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important," Gasoyan said. "This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes." A follow-up study is in the works to better track why patients stop taking their GLP-1 drugs, researchers said. More information Harvard Medical School has more on GLP-1 drugs. Copyright © 2025 HealthDay. All rights reserved.